Orano Med and Orbit Discovery have entered into a partnership for the discovery of specific peptide receptor radionuclide therapies against cancer cells and advance new radiopharmaceuticals development.
The US Food and Drug Administration (FDA) has issued additional guidance to Citius Pharmaceuticals on the resubmission of a biologics license application (BLA) for Lymphir (denileukin diftitox) to treat cutaneous T-cell lymphoma (CTCL).
Procaps Group has signed an agreement with BDR Pharmaceuticals International for 27 oncology molecules for Latin America, including 20 Tirosyne Kinase Inhibitors (TKIs).
Alentis Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its antibody ALE.C04 to treat patients with recurrent or metastatic, CLDN1-positive head and neck squamous cell carcinoma (HNSCC).
CanariaBio has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug product, MAb-AR20.5, targeting pancreatic cancer.
US-based clinical stage biotechnology company Abcuro has raised $155m from Series B financing round to further progress autoimmune pipeline.
Day One Biopharmaceuticals has signed a global license agreement and research partnership with Sprint Bioscience to advance Vaccinia-related kinase 1 (VRK1) programme.
Genprex has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its lead drug candidate, REQORSA Immunogene Therapy (quratusugene ozeplasmid), to treat small cell lung cancer (SCLC).
Bristol Myers Squibb has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) which recommended approval on Opdivo (nivolumab) for use as an adjuvant treatment in patients with completely resected stage IIB or IIC melanoma.
The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking approval of a new indication for Carvykti (ciltacabtagene autoleucel; cilta-cel) from the US Food and Drug Administration (FDA) through submission of a supplemental Biologics License Application (sBLA).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.